Erratum to Very low residual concentrations of rituximab long after infusion still induce positive B-cell complement-dependent cytotoxicity-crossmatch [Hum. Immunol., 74, (2013) 1616-1618] DOI: 10.1016/j.humimm.2013.08.278;Very low residual concentrations of rituximab long after infusion still induce positive B-cell complement-dependent cytotoxicity-crossmatch

Human Immunology

Volumn 74, Issue 12, 2013, Pages 1616-1618

  Philippe, Gatault ^a,b   Isabelle, Jollet ^c   Gilles, Paintaud ^a,d,e   Charlotte, Magdelaine ^c   Franck, Bridoux ^f   Yvon, Lebranchu ^a,b   Matthias, Büchler ^a,b   Guy, Touchard ^f,g   Antoine, Thierry ^f,g  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b FHU SUPORT   (France)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

^d UNIVERSITÉ DE TOURS   (France)

^e CNRS   (France)

^f POITIERS UNIVERSITY HOSPITAL   (France)

^g INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C4D; CREATININE; HLA A ANTIGEN; HLA B ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; RITUXIMAB;

ADULT; ARTICLE; B LYMPHOCYTE; CANCER SURGERY; CASE REPORT; CHRONIC GRAFT REJECTION; COMPLEMENT DEPENDENT CYTOTOXICITY; CREATININE BLOOD LEVEL; CYTOLYSIS; DIABETIC NEPHROPATHY; DRUG BLOOD LEVEL; DRUG MEGADOSE; GLOMERULOPATHY; HEMODIALYSIS; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY CARCINOMA; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; NEPHRECTOMY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEINURIA; RENAL GRAFT DYSFUNCTION; RETROSPECTIVE STUDY; SIDE EFFECT;

CDC; COMPLEMENT-DEPENDENT CYTOTOXICITY; CROSSMATCH; DONOR-SPECIFIC ANTIBODIES; DSA; HLA; HUMAN LEUCOCYTE ANTIGEN; INTRAVENOUS IMMUNOGLOBULIN; IVIG; SA; SINGLE ANTIGEN; XM;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; GRAFT REJECTION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 84888204986     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2014.12.014     Document Type: Erratum

References (16)

1. Vo A.A., Lukovsky M., Toyoda M., Wang J., Reinsmoen N.L., Lai C.H. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008, 359:242-251.
2. Shirakawa H., Ishida H., Shimizu T., Omoto K., Iida S., Toki D. The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experience. Clin Transplant 2011, 25:878-884.
3. Mulley W.R., Kanellis J. Understanding crossmatch testing in organ transplantation: A case-based guide for the general nephrologist. Nephrology (Carlton) 2011, 16(2):125-133.
4. Blasco H., Lalmanach G., Godat E., Maurel M.C., Canepa S., Belghazi M. Evaluation of a peptide ELISA for the detection of rituximab in serum. J Immunol Methods 2007, 325:127-139.
5. Melander C., Sallee M., Trolliet P., Candon S., Belenfant X., Daugas E. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009, 4:579-587.
6. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363:221-232.
7. Bomback A.S., Derebail V.K., McGregor J.G., Kshirsagar A.V., Falk R.J., Nachman P.H. Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol 2009, 4:734-744.
8. Roccatello D., Baldovino S., Rossi D., Mansouri M., Naretto C., Gennaro M. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004, 19:3054-3061.
9. Vo A.A., Peng A., Toyoda M., Kahwaji J., Cao K., Lai C.H. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010, 89:1095-1102.
10. Loupy A., Suberbielle-Boissel C., Zuber J., Anglicheau D., Timsit M.O., Martinez F. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation 2010, 89:1403-1410.
11. Fehr T., Rusi B., Fischer A., Hopfer H., Wuthrich R.P., Gaspert A. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009, 87:1837-1841.
12. Mulley W.R., Hudson F.J., Tait B.D., Skene A.M., Dowling J.P., Kerr P.G. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation 2009, 87:286-289.
13. Bearden C.M., Agarwal A., Book B.K., Sidner R.A., Gebel H.M., Bray R.A. Pronase treatment facilitates alloantibody flow cytometric and cytotoxic crossmatching in the presence of rituximab. Hum Immunol 2004, 65:803-809.
14. Tran L., Baars J.W., Aarden L., Beijnen J.H., Huitema A.D. Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. Hum Antibodies 2010, 19:7-13.
15. Cartron G., Blasco H., Paintaud G., Watier H., Le Guellec C. Pharmacokinetics of rituximab and its clinical use: thought for the best use?. Crit Rev Oncol Hematol 2007, 62:43-52.
16. Lai C.H., Cao K., Ong G., Naim M., Wan Q., et al. Antibody testing strategies for deceased donor kidney transplantation after immunomodulatory therapy. Transplantation 2011, 92:48-53.